NCT07326566 2026-03-19
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
46 trialsNCT05503797 2026-03-10
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
Phase 2 Recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT03050736 2025-09-04
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT02717962 2025-08-29
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT07120984 2025-08-13
IMAGLIO
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT04388475 2025-08-12
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
Phase 2 Completed
NCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT06687681 2025-04-09
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Kian Immune Cell Company
Phase 2 Recruiting
NCT04458272 2025-03-18
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
Daiichi Sankyo
Phase 2 Active not recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT03257631 2024-04-16
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
Phase 2 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT00704288 2024-02-05
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Exelixis
Phase 2 Completed
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02858895 2022-10-24
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
Phase 2 Completed
NCT01137604 2022-09-29
A Study in Subjects With Recurrent Malignant Glioma
Eisai Inc.
Phase 2 Completed
NCT05366062 2022-05-13
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
Epitopoietic Research Corporation
Phase 2 Not yet recruiting
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT01390948 2020-08-06
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Hoffmann-La Roche
Phase 2 Completed
NCT01967810 2020-02-25
ANG1005 in Patients With Recurrent High-Grade Glioma
Angiochem Inc
Phase 2 Completed
NCT01229644 2018-07-05
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
Arog Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00458601 2018-01-16
ACT III
Celldex Therapeutics
Phase 2 Completed
NCT00392171 2017-06-07
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01213407 2016-05-19
GBM-Vax
Activartis Biotech
Phase 2 Completed
NCT01898273 2015-09-09
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Cellectar Biosciences, Inc.
Phase 2 Terminated
NCT00427440 2015-04-27
A Phase II Study to Treat Advanced Malignant Glioma
Amgen
Phase 2 Completed
NCT00565721 2014-08-18
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
GE Healthcare
Phase 2 Completed
NCT00337883 2014-03-04
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Genentech, Inc.
Phase 2 Completed
NCT01778088 2014-02-25
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
Cellectar Biosciences, Inc.
Phase 2 Withdrawn
NCT00797940 2012-12-03
CLARITY-1
Protox Inc.
Phase 2 Withdrawn
NCT00409214 2012-11-16
Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litxâ„¢ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
Light Sciences Oncology
Phase 2 Completed
NCT00003775 2012-09-13
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
Pfizer
Phase 2 Completed
NCT00404495 2012-04-18
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
Pfizer
Phase 2 Completed
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00290771 2011-05-16
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Phase 2 Terminated
NCT00114309 2009-04-03
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
TransMolecular
Phase 2 Unknown
NCT00190723 2007-01-26
A Study of LY317615 in Patients With Brain Tumors
Eli Lilly and Company
Phase 2 Completed